Drug Profile
pp65-specific T cells - Miltenyi Biotec
Alternative Names: CMV-specific T-cells; IFN-gamma positive selected T-cellsLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Miltenyi Biotec GmbH; Samsung Medical Center
- Developer Miltenyi Biotec GmbH
- Class Cytomegalovirus vaccines; Immunotherapies; Peptide vaccines; T lymphocyte cell therapies
- Mechanism of Action Cell replacements; Immunologic cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cytomegalovirus infections
Most Recent Events
- 20 Mar 2020 Miltenyi Biotec withdraws a phase I/II trial for Cytomegalovirus infections in South Korea prior to enrolment (NCT02346617)
- 28 Feb 2019 No recent reports of development identified for preclinical development in Cytomegalovirus infections in Singapore (IV, Infusion)
- 13 Jan 2015 Preclinical trials in Cytomegalovirus infections treatment in Singapore before January 2015 (IV)